Cipla Q1 net up 10% at Rs 485 crore

Last Updated: Friday, August 9, 2013, 19:24

The company had posted a net profit of Rs 440.10 crore in the April-June quarter of 2012-13 fiscal.

Cipla spends Rs 274 cr to set up API facilities

Last Updated: Sunday, August 4, 2013, 17:45

Pharma major Cipla has spent Rs 274 crore towards setting up an Active Pharmaceutical Ingredient (API) R&D facility at Patalganga in Maharashtra, and commenced commercial production of anticancer APIs at Bommasandra, Bengalore and anti-ulcerant APIs at Kurkumbh in Maharashtra.

Drugs pricing row: HC extends relief to Cipla Ltd till Aug 27

Last Updated: Tuesday, July 30, 2013, 19:22

Delhi High Court on Tuesday extended the operation of its earlier order asking the Centre not to take coercive steps against pharma major Cipla Ltd which was told to replace stocks in the market with those carrying reduced prices within 45 days of new price notification.

HC asks Centre not to take coercive steps against Cipla

Last Updated: Friday, July 26, 2013, 20:35

The court, meanwhile, asked the firm to supply the revised price list of regulated medicines to its distributors, suppliers and retailers.

Cipla completes buyout of Cipla Medpro for Rs 2,707 cr

Last Updated: Tuesday, July 16, 2013, 15:45

Drug major Cipla on Tuesday said it has completed the buyout process of South African pharma firm Cipla Medpro for an aggregate consideration of Rs 2,707 crore.

Cipla will prioritise African markets for growth: CEO

Last Updated: Saturday, July 13, 2013, 12:18

Indian drug manufacturer Cipla will prioritise emerging markets across the African continent in its growth plans, the company's CEO Subhanu Saxena has said.

Expect completion of Cipla Medpro takeover by mid July: Cipla

Last Updated: Friday, June 28, 2013, 16:15

The acquisition of South African firm would help Cipla further strengthen its position in the African continent.

Cipla receives nod from SA authorities to acquire Cipla Medpro

Last Updated: Thursday, June 20, 2013, 19:49

Drug major Cipla Ltd Thursday said it has received approval from the authorities of South African and Botswana for the USD 512 million takeover offer to acquire Cipla Medpro.

Cipla grants global rights to Meda for nasal spray 'Dymista'

Last Updated: Wednesday, June 5, 2013, 20:20

Cipla Wednesday said it has granted the global commercialisation rights for its nasal spray 'Dymista' to Swedish partner Meda AB except for certain geographies.